### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

James Lee et al.

Serial No.: 09/104,063

Filed: 24 June 1998

For: NUCLEIC ACIDS ENCODING

PF4A RECEPTOR

Group Art Unit: 1646

Examiner: J. Ulm

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on

ctober 16, 2000

Yvonne E. Carter

#### **AMENDMENT TRANSMITTAL**

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated as shown below.

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Additional Fees
Total	12	-	20	0	18	\$0.00
Independent	4	-	4	0	78	\$0.00
Multiple dependent claim(s), if any 260						\$0.00
Total Fee Calculation						\$0.00

X No additional fee is required.
The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$-0-. A duplicate copy of this transmittal is enclosed.

X Petition for Extension of Time is enclosed.

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted, GENENTECH, INC.

Date: October 16, 2000

Richard B. Love Reg. No. 34,659

1 DNA Way

So. San Francisco, CA 94080-4990

Phone: (650) 225-5530 Fax: (650) 952-9881



NOV 0 2 2000

Patent Docket P0706P2C2D2

TECH CENTER 1600/2900

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

James Lee et al.

For:

Serial No.: 09/104,063

Filed: 24 June 1998

NUCLEIC ACIDS ENCODING

OCT 2 3 2000

PF4A RECEPTOR

Group Art Unit: 1646

Examiner: J. Ulm

**CERTIFICATE OF MAILING** 

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of

October 🞜

Patents, Washington, D.C. 20231 on

## **RESPONSE**

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Responsive to the Official Action mailed April 18, 2000, the period for responding to which being extended for three months from July 18, 2000 to October 18, 2000 by petition under 37 C.F.R. §1.136(a) enclosed herewith, Applicants respectfully request consideration of the following remarks.

#### **REMARKS**

Claims 20-23, 25 and 27-33 are pending in the application. Applicants respectfully request reconsideration of the outstanding rejections for the reasons that follow.

#### Rejection under 35 U.S.C. §101

Claims 20-23, 25 and 27-33 are rejected under 35 U.S.C. §101 as allegedly being drawn to an invention with no apparent or disclosed specific and substantial credible utility. In particular, the Office apparently contends that the application does not disclose the biological